insights_auto
Why is ATYR down 2.94%?
Dive Deeperchevron_right
ATYR:NASDAQ
aTyr Pharma Inc
$0.29
arrow_downward
-2.94%(-0.0089) 1D
$0.29
arrow_downward
-2.41% (-0.0071)todayPre-market
Closed: Oct 1, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ATYR...
Open
$0.30
High
$0.31
Low
$0.29
Mkt. cap
29.14M
Avg. vol.
5.64M
Volume
171.36K
52-wk high
$1.12
52-wk low
$0.27
EPS
-$0.62
Beta
0.53
Shares outstanding
98.09M
No. of employees
59
Open
$0.30
High
$0.31
Low
$0.29
Mkt. cap
29.14M
Avg. vol.
5.64M
Volume
171.36K
52-wk high
$1.12
52-wk low
$0.27
EPS
-$0.62
Beta
0.53
Shares outstanding
98.09M
No. of employees
59
News stories
From web sources and news partners
GlobeNewswire
·
29 minutes ago
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo Finance
·
55 minutes ago
Peter Brandt Calls XRP a “Fool Coin” Just Before 473 Million XRP Lists on Nasdaq. Does Payment Utility Count for Anything in the Price?
The Daily News | Texas' Oldest Newspaper
·
50 minutes ago
Traders work on the floor of the NYSE in New York
Seeking Alpha
·
1 hour ago
SPYM ETF: S&P 500 Monthly Dashboard For October
Profile
aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases.
The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease, a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients.
The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla. Wikipedia
About aTyr Pharma Inc